Aim: To retrospectively analyze the results of radical radiotherapy for patients with superficial esophageal cancer (SEC).
Patients And Methods: Forty-eight patients with SEC were reviewed. The median dose of external beam radiotherapy was 66 Gy (range, 30 to 70 Gy). Intraluminal brachytherapy was used in 10 patients, and 15 patients (31%) underwent chemotherapy. The median follow-up period was 28 months (range, 4 to 116 months).
Results: Sixteen patients had recurrence (11 patients: in-field local recurrence; 3 patients: regional lymph node recurrence; 2 patients: distant metastasis), and the 5-year local control (LC) rate was 74.2%. The 5-year overall survival and disease-free survival (DFS) rates were 44.5% and 48.6%, respectively. Patients with clinical N1 disease (5-year DFS: 0%) had significantly poorer DFS than patients with clinical N0 disease (5-year DFS: 51%, p=0.019).
Conclusion: Radical radiotherapy yielded relatively favorable LC rates in patients with SEC, and clinical N stage was a significant prognostic factor for DFS.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The current research status of the mechanisms and treatment of radioactive brain injury.
Am J Cancer Res
December 2024
Department of Oncology, Anhui Medical University Hefei 230000, Anhui, China.
Radioactive brain injury, a severe complication ensuing from radiotherapy for head and neck malignancies, frequently manifests as cognitive impairment and substantially diminishes patients' quality of life. Despite its profound impact, the pathogenesis of this condition remains inadequately elucidated, and efficacious treatments are notably absent in clinical practice. Consequently, contemporary interventions predominantly focus on symptom alleviation rather than achieving a radical cure or reversing the injury process.
View Article and Find Full Text PDFRadioprotective Effects of Vitamin C, Cimetidine, and Famotidine on Lipid Peroxidase and Hepatic Glutathione Levels in Mouse Liver.
Int J Cell Biol
January 2025
Department of Biotechnology and Plant Breeding, Sari Agricultural Sciences and Natural Resources University (SANRU), Sari, Iran.
Radiation therapy is one of the most effective treatments for approximately 60% of patients with cancer. During radiation exposure, the overproduction of reactive oxygen species (ROS) disrupts the lipid layer of the membrane, leading to subsequent peroxide radical formation. Cimetidine (Cim) and famotidine (Fam) are histamine H2 receptor antagonists (H2 blocker), also known as peptic ulcer drugs, that exert radioprotective effects.
View Article and Find Full Text PDFAngiosarcoma in an Arteriovenous Fistula Following Renal Transplantation: A Case Report and Literature Review.
Cureus
December 2024
Plastic and Reconstructive Surgery Department, Lebanese Hospital Geitawi University Medical Center, Beirut, LBN.
Angiosarcoma is a rare and aggressive malignant tumor arising from vascular or lymphatic endothelial cells. Angiosarcoma at an arteriovenous fistula site is exceptionally rare. We report a case of a 37-year-old male renal transplant recipient who developed a high-grade epithelioid angiosarcoma at the site of an arteriovenous fistula six years post-transplant.
View Article and Find Full Text PDFAn Overview of Patient-reported Outcomes for Men with Prostate Cancer: Results from the PIONEER Consortium.
Eur Urol Open Sci
January 2025
Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands.
Background And Objective: Patient-reported outcome measures (PROMs) are increasingly being used to capture the patients' perspective of their functional status and quality of life (QoL). Big data can help us better understand patient-reported outcomes (PROs). Using prospectively collected data from the Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) consortium, we aimed to describe the functional status and QoL in men with prostate cancer (PCa) treated with active surveillance (AS), radical prostatectomy (RP), and radiotherapy (RT), and to demonstrate the applicability of PROM data on a large scale and at a European level.
View Article and Find Full Text PDFImpact of Additional Active Treatment for Prostate Cancer on Health-related Quality of Life of Men: Results from the EUPROMS 2.0 1-year Follow-up Survey.
Eur Urol Open Sci
January 2025
Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Background And Objective: In 2019 and 2021, Europa Uomo initiated the Europa Uomo Patient Reported Outcome Study (EUPROMS) and the EUPROMS 2.0 survey, with the goal of collecting data on patients' self-reported perspective on physical and mental well-being outside of a clinical trial setting, to be able to investigate the burden of prostate cancer (PCa) treatment from a patient-to-patient perspective. Acknowledging the importance of collecting quality of life (QoL) follow-up data, a 1-yr follow-up (1yrFU) study was conducted to assess the effect of additional PCa treatment on QoL.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!